Saffron and Alzheimer

Phase 2

• Conditions: Mild to moderate Alzheimer.; Dementia in Alzheimer's disease

• Registration Number: IRCT138711051556N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Inclusion Criteria:
A diagnosis of probable Alzheimer’s disease according to the criteria of National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA); Presence of mild to moderate dementia [score of = 12 on the cognitive subscale of Alzheimer’s Disease Assessment Scale (ADAS-cog) and = 2 on Clinical Dementia Rating Scale (CDR)].

Exclusion Criteria

Concomitant diseases such as hypertension, congestive heart failure, non-insulin dependent diabetes mellitus and hypothyroidism; Patients with evidence of other neurodegenerative disorders; Any cardiovascular disease likely to prevent completion of the study; Clinically significant psychiatric diseases; Urinary outflow obstruction; Active peptic ulcer; Any history of epilepsy; Significant drug or alcohol misuse; Drugs with anticholinergic effects or cholinomimetic effects.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of Alzheimer. Timepoint: Every month. Method of measurement: ADAS-cog.

Secondary Outcome Measures

Name	Time	Method
Severity of Alzheimer. Timepoint: Every Month. Method of measurement: CDR-SB.